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LETTERS TO THE EDITOR
Regarding “Impact of diabetes mellitus on outcomes
of superficial femoral artery endoluminal
interventions”
In a recent study, Bakken et al concluded that endoluminal
therapy for superficial femoral artery (SFA) occlusive disease yields
lower assisted patency rates and higher restenosis rates for those
presenting with claudication and more advanced diabetes.1 In
those with critical limb ischemia, limb salvage rates are lower in
diabetic patients, despite comparable patency rates to non-diabetic
patients. These results are of great importance as a significant
portion of any modern vascular practice consists of diabetic pa-
tients.
We recently analyzed our results for endoluminal therapy with
expanded polytetrafluorethylene (ePTFE)-covered endografts for
superficial femoral artery (SFA) occlusive disease (mix of claudi-
cants and critical limb ischemia). Stents with ePTFE-endo-lining
were developed to reduce the rate of in-stent stenosis based on its
characteristics of biocompatability observed in previous studies
using ePTFE bypass grafts. In our prospective analysis of 96
patients during 2-years follow-up, we observed no difference in
primary patency rates between diabetics (66%, n  33) and non-
diabetics (74%, n  63). However, the assisted patency rates were
lower in diabetics (68%) compared to non-diabetics (86%, P 
.02). Also in ePTFE-covered endografts, diabetes seems to confer
an increased risk for restenosis and so a significantly reduced
cumulative patency rate.
The authors separated their diabetic population into insulin-
dependent and non-insulin-dependent diabetic patients, assuming
that those taking more insulin had more severe diabetes. However,
insulin dependency seems to not be a very good way to stratify
diabetic patients to their diabetes severity. A more biological based
method is the analysis of tissue advanced glycation endproducts
(AGEs) accumulation. AGEs are a heterogeneous group of com-
pounds formed by the reaction of sugars (hyperglycemia) with
proteins, lipids (hyperlipidemia), and oxidative stress (eg, from
smoking). Assessment of tissue AGE accumulation serves as a
measure of cumulative metabolic stress and protein damage, and so
reflects diabetes severity (Fig).2 Furthermore, AGEs are related to
long-term complications in diabetes, including peripheral artery
occlusive disease and stent patency.3 AGEs not only play a major
role in the development of (chronic) atherosclerosis, but also
contribute to the formation of neointimal hyperplasia following
acute vessel wall injury. In diabetic patients receiving cardiac stents,
an elevated level of serum AGEs appears to be an independent risk
factor for the development of angiographic re-stenosis.4
The authors furthermore observed lower limb salvage rates in
diabetic patients compared to non-diabetic patients with critical
limb ischemia, despite equivalent patency rates for both groups.
We have recently shown in diabetic patients that AGE accumula-
tion is related to the severity of diabetic neuropathy as well as the
severity of diabetic foot ulceration.5 We and others have shown
that AGEs predict the development and progression of microvas-
cular complications, such as diabetic neuropathy.6 Finally, block-
age of AGEs accelerates wound closure. So, AGE accumulation
may play a role in diabetic foot ulceration by its effects on neurop-
athy, vascular disease, and delayed wound repair.
In conclusion, lower patency rates and lower limb salvage rates
are observed in diabetic patients with SFA occlusive disease. The
assessment of AGE accumulation may serve as a simple measure for
diabetes severity. Furthermore, AGE levels are strongly related to
stent patency rates and foot ulceration in diabetes.
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Reply
We appreciate the comments of Meerwaldt et al on our recent
article. We did not use a primary stenting policy in our study
because the literature and current level 1 evidence do not support
their use. The use of covered stents has several theoretic advan-
tages, but their use is not supported by adequately powered
randomized clinical trials. Irrespective of these concerns, the anec-
dotal data presented on covered stents further supports our find-
Fig. Advanced glycation endproducts (AGEs) show the cumula-
tive damage to proteins by hyperglycemia, hyperlipidemia, oxida-
tive stress, and decreased renal clearance of AGE-precursors. AGE
accumulation leads to atherosclerosis and microvascular complica-
tions through their effect on extracellular proteins (eg, collagen
and lipoproteins) and by their interaction with specific receptors,
inducing inflammation and endothelial dysfunction.3
774
ings that diabetes appears to be a negative prognosticator when
percutaneous superficial femoral artery interventions are examined
and that use of an additional adjunctive modality does not correct
the underlying biology. Lenti et al1 have shown similar primary
patency rates as Meerwaldt et al but did find that critical ischemia
was associated with poorer outcomes.
In our article, we categorized our patient population into
claudicant and critical limb cohorts to avoid the confusion in the
data set presented by Meerwaldt et al. Their report is of a hetero-
geneous population of patients with claudication and critical isch-
emia and as such cannot be compared directly with our data set or
with that of Lenti et al. It is vital not to confuse the subject with
mixed populations because this leads to misinterpretations. We
would have also been interested to know if there was a correlation
with advanced glycation end products (AGE) and outcomes in this
population and if their limb salvage rates matched our findings in
the diabetic patients with critical ischemia. We agree with the
authors that a more refined classification of diabetes is important.
The need for insulin therapy is a significant differentiation factor in
the adult population.
Unfortunately, AGE measurements are not standard clinical
practice, and thus, we used a system that would be applicable to all
practitioners in the field. Meerwaldt et al did not show any corre-
lation with AGE levels and outcomes and did not separate out their
population into insulin-dependent and non-insulin-dependent di-
abetes mellitus. However, there is convincing evidence in vitro and
in vivo of the impact of AGE on vessel wall biology. Up-regulation
of AGE receptor and increased expression of AGEs occur in the
vessel wall after injury in animals.2,3 Choi et al4 have shown in
diabetic patients receiving coronary stenting that an elevated level
of serumAGEs is an independent risk factor for the development of
angiographic restenosis in the coronary circulation. AGEs are
associated with enhanced inflammation, and other markers of
inflammation such as C-reactive protein have been shown to be
associated with decreased patency of SFA interventions.5,6
Whether the AGE data from coronary stenting is referable to the
angioplasty of the superficial femoral artery is questionable.
The authors raise a valid point that severity of foot ulceration
and neuropathy do significantly influence the outcomes of foot
salvage in diabetic patients with tissue loss. In a subgroup analysis,
we did demonstrate that the presence of tissue loss did influence
final limb salvage. AGEs are associated with vessel wall changes and
have been associated with neuropathy, which may also be due to a
microangiopathy. Whether this is cause and effect or an association
remains to be determined, because the cause of the diabetic foot is
multifactorial, and limb loss is most often driven by superimposed
infections. We appreciate the authors’ thoughtful comments on
our article and their contribution to the further understanding of
the role of diabetes in the management of the patients with SFA
disease.
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Regarding “A randomized trial of carotid stenting
with and without cerebral protection”
Congratulations to the Journal of Vascular Surgery for publish-
ing the excellent, albeit small, article by Barbato JE, Dillavou E,
Horowitz MB, Jovin TG, Kant E, David S, and Makaroun MS. A
randomized trial of carotid stentingwith andwithout cerebral protec-
tion. J Vasc Surg 2008;47:760-5. Diffusion weighted magnetic reso-
nance imaging (MRI) has consistently demonstrated a high rate of
ipsilateral and contralateral infarction following carotid stenting.
Whether it is 40%1 or 70% as in the current study, it is an attention-
getting fact. Others have shown a lack of correlation between filter-
captured debris and the incidence of infarcts,2 quite possibly because
placement of the filter itself causes some embolization. For those who
defend carotid stents or filters, the best rebuttal to these datawould be
additional well controlled studies using MRI. So far, the incidence of
infarcts after CEA has been about one tenth that of stents with or
without filters. In the meantime, is it not appropriate to inform
patients that they are likely to have several small infarcts in their brain
when a stent is placed? How many surgeons would accept this for
themselves? The current article will surely have its highly motivated
detractors but these data argue well that carotid stents and filters
require further study through scientifically conducted, unbiased trials
that should include MRI as an endpoint.3
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Regarding “Multidisciplinary approach in the
management of a giant arteriovenous malformation in
the right axillary region”
In this article,1 the authors have made an excellent contribu-
tion to the contemporary management of the arteriovenous mal-
formation (AVM) lesion utilizing sound judgment and appropriate
decision making, addressing three critical issues.
First, they implemented a “multidisciplinary approach”2 to
evaluate and address a limb-threatening AVM lesion where an
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